Slingshot members are tracking this event:
Celgene (CELG) Expects Phase 3 RADIANCE Confirmatory Trial Data in Q2 Evaluating Oral Ozanimod in Patients with Relapsing Multiple Sclerosis
Slingshot Insights Explained
May 22, 2017
Don’t see a project related to the catalyst you care about?
Related Keywords Phase 3, Confirmatory Trial, Ozanimod, Oral, Relapsing Multiple Sclerosis, Radiance